Acacia Pharma Ltd
Quick facts
Phase 3 pipeline
- APD421 · Oncology / Anesthesia
APD421 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center. - APD421- Amisulpride for IV injection · Gastroenterology / Perioperative Medicine
APD421 is an intravenous formulation of amisulpride, a dopamine D2/D3 receptor antagonist that blocks dopamine signaling to prevent postoperative nausea and vomiting.
Phase 2 pipeline
- APD209
- APD403 IV · Anesthesiology
APD403 IV is an anesthetic agent that works by blocking N-methyl-D-aspartate (NMDA) receptors. - APD403 oral · Anesthesiology
APD403 is a selective α2δ-1 subunit ligand. - APD405
- APD515 · Oncology / Gastroenterology
APD515 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces nausea and vomiting by blocking substance P signaling in the chemoreceptor trigger zone and vomiting center.
Phase 1 pipeline
- 14C-APD421
- Amisulpride IV · Neurology
Dopamine D2/D3 receptor antagonist
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Acacia Pharma Ltd
What is Acacia Pharma Ltd's pipeline?
Acacia Pharma Ltd has 2 drugs in Phase 3, 5 in Phase 2, 2 in Phase 1. Late-stage candidates include APD421, APD421- Amisulpride for IV injection.
Related
- Sector hub: All tracked pharma companies